CN103109192A - 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物 - Google Patents
用于妊娠性高血压和先兆子痫的预后和风险评估的标志物 Download PDFInfo
- Publication number
- CN103109192A CN103109192A CN2011800301041A CN201180030104A CN103109192A CN 103109192 A CN103109192 A CN 103109192A CN 2011800301041 A CN2011800301041 A CN 2011800301041A CN 201180030104 A CN201180030104 A CN 201180030104A CN 103109192 A CN103109192 A CN 103109192A
- Authority
- CN
- China
- Prior art keywords
- pro
- fragment
- eclampsia
- adm
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 74
- 238000004393 prognosis Methods 0.000 title claims abstract description 18
- 238000012502 risk assessment Methods 0.000 title claims abstract description 15
- 201000005624 HELLP Syndrome Diseases 0.000 title abstract description 4
- 206010070538 Gestational hypertension Diseases 0.000 title abstract description 3
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 title abstract 2
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 claims description 48
- 230000035935 pregnancy Effects 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 23
- 210000002381 plasma Anatomy 0.000 claims description 14
- 238000011161 development Methods 0.000 claims description 10
- 210000002700 urine Anatomy 0.000 claims description 8
- 108030001694 Pappalysin-1 Proteins 0.000 claims description 6
- 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004291 uterus Anatomy 0.000 claims description 6
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 5
- 102100035194 Placenta growth factor Human genes 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 102000036663 ADAM12 Human genes 0.000 claims description 4
- 108091007507 ADAM12 Proteins 0.000 claims description 4
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 claims description 4
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 claims description 4
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 4
- -1 PP-13 Proteins 0.000 claims description 4
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 claims description 4
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 210000001367 artery Anatomy 0.000 claims description 4
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 3
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 101001076604 Homo sapiens Inhibin alpha chain Proteins 0.000 claims description 3
- 102100025885 Inhibin alpha chain Human genes 0.000 claims description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 3
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims description 3
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims description 3
- 108010023082 activin A Proteins 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 208000002151 Pleural effusion Diseases 0.000 claims description 2
- 102000002852 Vasopressins Human genes 0.000 claims description 2
- 108010004977 Vasopressins Proteins 0.000 claims description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 2
- 229960004407 chorionic gonadotrophin Drugs 0.000 claims description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims description 2
- 229940072644 pitressin Drugs 0.000 claims description 2
- 102100036836 Natriuretic peptides B Human genes 0.000 claims 1
- 101710187802 Natriuretic peptides B Proteins 0.000 claims 1
- 101150062285 PGF gene Proteins 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 abstract description 11
- 102400000686 Endothelin-1 Human genes 0.000 description 43
- 101800004490 Endothelin-1 Proteins 0.000 description 43
- 206010020772 Hypertension Diseases 0.000 description 36
- 239000000523 sample Substances 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 21
- 230000035945 sensitivity Effects 0.000 description 16
- 239000000975 dye Substances 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000035487 diastolic blood pressure Effects 0.000 description 7
- 230000001631 hypertensive effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010001580 Albuminuria Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 description 3
- 208000002296 eclampsia Diseases 0.000 description 3
- 230000008694 endothelial dysfunction Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 235000006693 Cassia laevigata Nutrition 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000522641 Senna Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229910052761 rare earth metal Inorganic materials 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 108010008126 C-terminal proendothelin-1 Proteins 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 102400000060 Copeptin Human genes 0.000 description 1
- 101800000115 Copeptin Proteins 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032943 Fetal Distress Diseases 0.000 description 1
- 206010016855 Foetal distress syndrome Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010018713 Gravitational oedema Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035138 Placental insufficiency Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000999 acridine dye Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 235000021156 lunch Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical group C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical group C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MYIOYATURDILJN-UHFFFAOYSA-N rhodamine 110 Chemical compound [Cl-].C=12C=CC(N)=CC2=[O+]C2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O MYIOYATURDILJN-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 150000003732 xanthenes Chemical class 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/02—Measuring pulse or heart rate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10290332.5 | 2010-06-18 | ||
| EP10290332 | 2010-06-18 | ||
| PCT/EP2011/003018 WO2011157445A1 (en) | 2010-06-18 | 2011-06-17 | Markers for the prognosis and risk assessment of pregnancy-induced hypertension and preeclampsia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103109192A true CN103109192A (zh) | 2013-05-15 |
Family
ID=42668216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800301041A Pending CN103109192A (zh) | 2010-06-18 | 2011-06-17 | 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130177901A1 (pt) |
| EP (1) | EP2583106A1 (pt) |
| JP (1) | JP5684904B2 (pt) |
| CN (1) | CN103109192A (pt) |
| BR (1) | BR112012032406A2 (pt) |
| RU (1) | RU2013102112A (pt) |
| WO (1) | WO2011157445A1 (pt) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103513042A (zh) * | 2013-09-23 | 2014-01-15 | 中国科学院动物研究所 | 用于预测或早期诊断妊娠高血压疾病的试剂盒 |
| CN103760342A (zh) * | 2014-01-28 | 2014-04-30 | 成都创宜生物科技有限公司 | 检测妊娠子痫前期的免疫层析试纸 |
| CN106716134A (zh) * | 2014-09-17 | 2017-05-24 | 沃拉克有限公司 | 确定早产风险的方法 |
| WO2017197573A1 (en) * | 2016-05-17 | 2017-11-23 | Ldx Prognostics Limited Co. | Methods and compositions for providing preeclampsia assessment |
| WO2018076134A1 (en) * | 2016-10-24 | 2018-05-03 | Ldx Prognostics Limited Co. | Methods and kits for providing a preeclampsia assessment and prognosing preterm birth |
| CN108614118A (zh) * | 2018-04-17 | 2018-10-02 | 段天雄 | 妊娠期高血压疾病相关标志物组合物及其应用 |
| CN108776226A (zh) * | 2018-04-08 | 2018-11-09 | 邓成 | 晚发型子痫前期快速筛查用试纸和试剂盒 |
| CN112816702A (zh) * | 2020-12-29 | 2021-05-18 | 苏州百志生物科技有限公司 | 一种检测人体液中可溶性内皮因子含量的试剂盒 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007233320B2 (en) | 2006-04-04 | 2013-12-12 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| WO2010144358A1 (en) | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
| RU2480762C1 (ru) * | 2012-03-19 | 2013-04-27 | Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "НИИ ОММ" Минздравсоцразвития России) | Способ прогноза формирования эссенциальной артериальной гипертензии у женщин с гипертензивными нарушениями при беременности |
| SG11201501145SA (en) | 2012-08-13 | 2015-04-29 | Otago Innovation Ltd | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
| US20150330989A1 (en) * | 2012-11-15 | 2015-11-19 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
| JP2016507753A (ja) | 2013-02-08 | 2016-03-10 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 子癇前症発症を予測する診断ツール |
| US20140273025A1 (en) * | 2013-03-15 | 2014-09-18 | Wallac Oy | System and method for determining risk of pre-eclampsia based on biochemical marker analysis |
| ES2830036T3 (es) * | 2013-03-20 | 2021-06-02 | Sphingotec Gmbh | Adrenomedulina para guiar una terapia de disminución de la presión sanguínea |
| RU2545760C2 (ru) * | 2013-05-31 | 2015-04-10 | Закрытое акционерное общество "Протеинсинтез" | Способ прогнозирования преэклампсии у беременных с плацентарной недостаточностью |
| RU2565405C1 (ru) * | 2014-05-07 | 2015-10-20 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | СПОСОБ ПРОГНОЗИРОВАНИЯ УРОВНЯ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ У ЖЕНЩИН НА СРОКЕ РОДОРАЗРЕШЕНИЯ С ИСПОЛЬЗОВАНИЕМ ГЕНЕТИЧЕСКОГО ПОЛИМОРФИЗМА 4a/4b eNOS |
| RU2558465C1 (ru) * | 2014-07-15 | 2015-08-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Министерства здравоохранения РФ | Способ доклинической диагностики преэклампсии |
| WO2016149759A1 (en) * | 2015-03-23 | 2016-09-29 | Adelaide Research & Innovation Pty Ltd | Methods and systems for determining risk of a pregnancy complication occurring |
| EP3443355B1 (en) * | 2016-04-13 | 2020-06-03 | Abbott Laboratories | Cardiac troponin i detection during pregnancy for cardiovascular disease identification and risk assessment |
| US20190128895A1 (en) * | 2016-04-20 | 2019-05-02 | Ldx Prognostics Limited Co. | Methods and compositions for prognosing preterm birth |
| GR20170100034A (el) * | 2017-01-27 | 2018-10-22 | Αθανασιος Κωνσταντινου Αναγνωστοπουλος | Η πρωτεϊνη c9jv37 ως δεικτης για την προγνωση και διαγνωση της προεκλαμψιας κατα την διαρκεια της κυησης |
| US20200124612A1 (en) * | 2017-04-11 | 2020-04-23 | University Of Iowa Research Foundation | Detection of predictors of preeclampsia |
| RU2691114C1 (ru) * | 2018-03-20 | 2019-06-11 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития преэклампсии в поздние сроки беременности |
| GB201910133D0 (en) * | 2019-07-15 | 2019-08-28 | Univ Tartu | Method of prognosing and diagnosing preeclampsia |
| CN110387414B (zh) * | 2019-07-19 | 2022-09-30 | 广州市达瑞生物技术股份有限公司 | 一种利用外周血游离dna预测妊娠期糖尿病的模型 |
| RU2741730C1 (ru) * | 2020-10-12 | 2021-01-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации | Способ прогнозирования риска развития тяжелых осложнений преэклампсии |
| RU2753463C1 (ru) * | 2021-02-28 | 2021-08-16 | федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се | Способ прогнозирования тяжести течения ранней преэклампсии |
| JP2024519321A (ja) * | 2021-05-07 | 2024-05-10 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重篤患者におけるコルチコステロイドの療法層別化のための成熟アドレノメデュリン |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997007214A1 (en) * | 1995-08-18 | 1997-02-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology |
| CN1723289A (zh) * | 2003-01-17 | 2006-01-18 | 香港中文大学 | 作为妊娠相关病症的诊断标志物的循环mRNA |
| EP1619505A2 (en) * | 2004-07-22 | 2006-01-25 | BRAHMS Aktiengesellschaft | Method for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| CN101643785A (zh) * | 2009-06-18 | 2010-02-10 | 中国人民解放军第二军医大学 | 用于妊娠高血压综合症检测的hsa-mir-210试剂盒及检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004051847B4 (de) * | 2004-10-25 | 2008-09-18 | Dade Behring Marburg Gmbh | Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen |
| US20080071151A1 (en) * | 2006-06-30 | 2008-03-20 | Sogin David C | Method and Apparatus for Diagnosing Pre-eclampsia |
-
2011
- 2011-06-17 EP EP11729558.4A patent/EP2583106A1/en not_active Withdrawn
- 2011-06-17 US US13/704,654 patent/US20130177901A1/en not_active Abandoned
- 2011-06-17 CN CN2011800301041A patent/CN103109192A/zh active Pending
- 2011-06-17 WO PCT/EP2011/003018 patent/WO2011157445A1/en active Application Filing
- 2011-06-17 BR BR112012032406A patent/BR112012032406A2/pt not_active IP Right Cessation
- 2011-06-17 JP JP2013514598A patent/JP5684904B2/ja not_active Expired - Fee Related
- 2011-06-17 RU RU2013102112/15A patent/RU2013102112A/ru unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997007214A1 (en) * | 1995-08-18 | 1997-02-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology |
| CN1723289A (zh) * | 2003-01-17 | 2006-01-18 | 香港中文大学 | 作为妊娠相关病症的诊断标志物的循环mRNA |
| EP1619505A2 (en) * | 2004-07-22 | 2006-01-25 | BRAHMS Aktiengesellschaft | Method for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| CN101643785A (zh) * | 2009-06-18 | 2010-02-10 | 中国人民解放军第二军医大学 | 用于妊娠高血压综合症检测的hsa-mir-210试剂盒及检测方法 |
Non-Patent Citations (1)
| Title |
|---|
| SIMON GRILL ET AL: "Potential markers of preeclampsia – a review", 《REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY》, vol. 7, 14 July 2009 (2009-07-14), XP021058967, DOI: doi:10.1186/1477-7827-7-70 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103513042A (zh) * | 2013-09-23 | 2014-01-15 | 中国科学院动物研究所 | 用于预测或早期诊断妊娠高血压疾病的试剂盒 |
| WO2015039419A1 (zh) * | 2013-09-23 | 2015-03-26 | 中国科学院动物研究所 | 用于预测或早期诊断妊娠高血压疾病的试剂盒 |
| CN103760342A (zh) * | 2014-01-28 | 2014-04-30 | 成都创宜生物科技有限公司 | 检测妊娠子痫前期的免疫层析试纸 |
| CN103760342B (zh) * | 2014-01-28 | 2016-01-27 | 成都创宜生物科技有限公司 | 检测妊娠子痫前期的免疫层析试纸 |
| CN106716134A (zh) * | 2014-09-17 | 2017-05-24 | 沃拉克有限公司 | 确定早产风险的方法 |
| WO2017197573A1 (en) * | 2016-05-17 | 2017-11-23 | Ldx Prognostics Limited Co. | Methods and compositions for providing preeclampsia assessment |
| CN109196362A (zh) * | 2016-05-17 | 2019-01-11 | 苏州爱尔迪思生物科技有限公司 | 用于提供子痫前期评估的方法和组合物 |
| WO2018076134A1 (en) * | 2016-10-24 | 2018-05-03 | Ldx Prognostics Limited Co. | Methods and kits for providing a preeclampsia assessment and prognosing preterm birth |
| CN108776226A (zh) * | 2018-04-08 | 2018-11-09 | 邓成 | 晚发型子痫前期快速筛查用试纸和试剂盒 |
| CN108614118A (zh) * | 2018-04-17 | 2018-10-02 | 段天雄 | 妊娠期高血压疾病相关标志物组合物及其应用 |
| CN108614118B (zh) * | 2018-04-17 | 2021-08-27 | 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） | 妊娠期高血压疾病相关标志物组合物及其应用 |
| CN112816702A (zh) * | 2020-12-29 | 2021-05-18 | 苏州百志生物科技有限公司 | 一种检测人体液中可溶性内皮因子含量的试剂盒 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013533965A (ja) | 2013-08-29 |
| BR112012032406A2 (pt) | 2016-10-25 |
| WO2011157445A1 (en) | 2011-12-22 |
| EP2583106A1 (en) | 2013-04-24 |
| RU2013102112A (ru) | 2014-07-27 |
| JP5684904B2 (ja) | 2015-03-18 |
| US20130177901A1 (en) | 2013-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103109192A (zh) | 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物 | |
| EP2368119B1 (en) | Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers | |
| US11307209B2 (en) | Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2 | |
| WO2008046160A1 (en) | Assay for the detection of biomarkers associated with pregnancy related conditions | |
| CN103415769A (zh) | 用于妊娠性高血压疾病的生物标志物和参数 | |
| US20170285041A1 (en) | Method for determining risk of pre-eclampsia | |
| JP4734306B2 (ja) | ナトリウム利尿ペプチドおよび胎盤増殖因子／可溶性ｖｅｇｆ受容体を用いた、妊婦での心疾患に関連した心機能不全と胎盤関連心機能不全とを区別するための方法 | |
| Duhig et al. | Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: the PEACOCK study | |
| US11874282B2 (en) | IGFBP-7 as a marker of preeclampsia | |
| US20170122959A1 (en) | Early placenta insulin-like peptide (pro-epil) | |
| US20140127703A1 (en) | Method for Diagnosing Preeclampsia | |
| Miller et al. | Advances in preeclampsia testing | |
| KR102112945B1 (ko) | 일반 집단에서 lvh 로의 진행자 확인을 위한 가용성 st2 | |
| WO2020016441A1 (en) | Prediction of preeclampsia based on igfbp-7 | |
| WO2013050383A2 (en) | In vitro method to determine the risk of a pregnant woman of carrying a fetus with fetal aneuploidy | |
| Celik et al. | Do Triple Test Results Assess Risk for Adverse Pregnancy Outcomes? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1183706 Country of ref document: HK |
|
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20160622 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1183706 Country of ref document: HK |